Datasets:
output stringlengths 5 24.3k | instruction stringlengths 33 308 | system stringclasses 1 value |
|---|---|---|
1. Allergens [therapeutic use]; 2. Cattle; 3. *Eczema [drug therapy, prevention & control]; 4. Emollients [therapeutic use]; 5. *Food Hypersensitivity [prevention & control]; 6. *Milk Hypersensitivity; | Provide MESH terms for the study
Skin care interventions in infants for preventing eczema and food allergy | You are a research assistant. Based on the question please provide appropriate answers |
1. Antifungal Agents [therapeutic use]; 2. *Aspergillosis, Allergic Bronchopulmonary [complications, drug therapy]; 3. Aspergillus fumigatus; 4. *Cystic Fibrosis [complications, drug therapy]; 5. Itraconazole [therapeutic use]; | Provide MESH terms for the study
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis | You are a research assistant. Based on the question please provide appropriate answers |
1. Antibodies, Anti-Idiotypic; 2. Antifungal Agents [therapeutic use]; 3. *Aspergillosis, Allergic Bronchopulmonary [drug therapy]; 4. *Cystic Fibrosis [complications, drug therapy]; 5. Prospective Studies; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis | You are a research assistant. Based on the question please provide appropriate answers |
1. Bias; 2. *Eczema; 3. *Hypersensitivity, Immediate; 4. Pertussis Vaccine [adverse effects]; 5. *Whooping Cough; | Provide MESH terms for the study
Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children | You are a research assistant. Based on the question please provide appropriate answers |
1. Bias; 2. Body Height; 3. Dietary Fats [adverse effects, *analysis]; 4. Head [growth & development]; 5. Infant Food [adverse effects, *analysis]; 6. Infant Nutritional Physiological Phenomena; 7. Infant, Low Birth Weight [*growth & development]; 8. Infant, Premature [growth & development]; 9. Randomized Controlled Trials as Topic; 10. Triglycerides [adverse effects, *analysis, chemistry]; 11. Weight Gain; | Provide MESH terms for the study
High versus low medium chain triglyceride content of formula for promoting short‐term growth of preterm infants | You are a research assistant. Based on the question please provide appropriate answers |
1. Asthma [*therapy]; 2. Disease Progression; 3. Hospitalization [statistics & numerical data]; 4. Placebos [therapeutic use]; 5. Pollen; 6. Pyroglyphidae; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Rhinitis, Allergic [therapy]; 10. Sublingual Immunotherapy [adverse effects, *methods]; | Provide MESH terms for the study
Sublingual immunotherapy for asthma | You are a research assistant. Based on the question please provide appropriate answers |
1. Energy Intake; 2. *Enterocolitis, Necrotizing [epidemiology, prevention & control]; 3. *Infant Formula; 4. *Infant Nutritional Physiological Phenomena; 5. *Infant, Low Birth Weight; 6. *Infant, Premature; 7. Length of Stay; 8. Weight Gain; | Provide MESH terms for the study
Dilute versus full‐strength formula in exclusively formula‐fed preterm or low birth weight infants | You are a research assistant. Based on the question please provide appropriate answers |
1. Eczema [*therapy]; 2. Probiotics [*therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Symptom Assessment; 5. Treatment Outcome; | Provide MESH terms for the study
Probiotics for treating eczema | You are a research assistant. Based on the question please provide appropriate answers |
1. *Dietary Proteins; 2. Asthma [epidemiology]; 3. Breast Feeding; 4. Dermatitis, Atopic [epidemiology]; 5. Food Hypersensitivity [*prevention & control]; 6. Infant Formula [*chemistry]; 7. Milk; 8. Milk Hypersensitivity [prevention & control]; 9. Milk, Human; 10. Protein Hydrolysates [*administration & dosage]; 11. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Infant formulas containing hydrolysed protein for prevention of allergic disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Administration, Oral; 2. Desensitization, Immunologic [adverse effects, *methods]; 3. Egg Hypersensitivity [*therapy]; 4. Egg Proteins, Dietary [*administration & dosage, immunology]; 5. Epinephrine [therapeutic use]; 6. Immunoglobulin E [immunology]; 7. Randomized Controlled Trials as Topic; 8. Sublingual Immunotherapy [adverse effects, methods]; | Provide MESH terms for the study
Oral and sublingual immunotherapy for egg allergy | You are a research assistant. Based on the question please provide appropriate answers |
1. *Dietary Supplements; 2. Asthma [prevention & control]; 3. Dermatitis [prevention & control]; 4. Fatty Acids, Unsaturated [*administration & dosage]; 5. Food Hypersensitivity [prevention & control]; 6. Hypersensitivity [epidemiology, *prevention & control]; 7. Prevalence; 8. Randomized Controlled Trials as Topic; 9. Rhinitis, Allergic [epidemiology, prevention & control]; | Provide MESH terms for the study
Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy | You are a research assistant. Based on the question please provide appropriate answers |
1. Allergens [*therapeutic use]; 2. Dermatitis, Atopic [*therapy]; 3. Dermatophagoides farinae; 4. Dermatophagoides pteronyssinus; 5. Desensitization, Immunologic [*methods]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Specific allergen immunotherapy for the treatment of atopic eczema | You are a research assistant. Based on the question please provide appropriate answers |
1. *Leukocyte Reduction Procedures; 2. Cause of Death; 3. Erythrocyte Transfusion [*adverse effects]; 4. Infections [etiology]; 5. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion | You are a research assistant. Based on the question please provide appropriate answers |
1. Desensitization, Immunologic [*methods]; 2. Food Hypersensitivity [etiology, *therapy]; 3. Fruit [*adverse effects]; 4. Malus [*adverse effects]; 5. Pyrus [*adverse effects]; 6. Randomized Controlled Trials as Topic; 7. Sublingual Immunotherapy [methods]; | Provide MESH terms for the study
Immunotherapy (oral and sublingual) for food allergy to fruits | You are a research assistant. Based on the question please provide appropriate answers |
1. *Infant, Very Low Birth Weight; 2. Enema [methods]; 3. Enteral Nutrition [*adverse effects]; 4. Gestational Age; 5. Glycerol [*therapeutic use]; 6. Laxatives [*therapeutic use]; 7. Meconium; 8. Randomized Controlled Trials as Topic; 9. Suppositories; | Provide MESH terms for the study
Glycerin laxatives for prevention or treatment of feeding intolerance in very low birth weight infants | You are a research assistant. Based on the question please provide appropriate answers |
1. *Dietary Supplements; 2. Age Factors; 3. Fatty Acids, Omega‐3 [*administration & dosage]; 4. Food Hypersensitivity [prevention & control]; 5. Hypersensitivity [*prevention & control]; 6. Immunoglobulin E [immunology]; 7. Postnatal Care; 8. Prenatal Care; 9. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Maternal prenatal and/or postnatal n‐3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood | You are a research assistant. Based on the question please provide appropriate answers |
1. Cetirizine [therapeutic use]; 2. Cyproheptadine [analogs & derivatives, therapeutic use]; 3. Histamine H1 Antagonists [adverse effects, *therapeutic use]; 4. Hydroxyzine [therapeutic use]; 5. Loratadine [analogs & derivatives, therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Urticaria [*drug therapy]; | Provide MESH terms for the study
H1‐antihistamines for chronic spontaneous urticaria | You are a research assistant. Based on the question please provide appropriate answers |
1. Adrenal Cortex Hormones [therapeutic use]; 2. Anti‐Asthmatic Agents [administration & dosage, *therapeutic use]; 3. Antibodies, Anti‐Idiotypic [administration & dosage, *therapeutic use]; 4. Antibodies, Monoclonal, Humanized [administration & dosage, *therapeutic use]; 5. Asthma [*drug therapy, immunology]; 6. Chronic Disease; 7. Immunoglobulin E [blood, *immunology]; 8. Injections, Subcutaneous; 9. Omalizumab; 10. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Omalizumab for asthma in adults and children | You are a research assistant. Based on the question please provide appropriate answers |
1. *Infant Formula; 2. *Prebiotics; 3. Asthma [prevention & control]; 4. Eczema [prevention & control]; 5. Food Hypersensitivity [prevention & control]; 6. Hypersensitivity [*prevention & control]; 7. Milk Hypersensitivity [prevention & control]; 8. Oligosaccharides [*therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Urticaria [prevention & control]; | Provide MESH terms for the study
Prebiotics in infants for prevention of allergy | You are a research assistant. Based on the question please provide appropriate answers |
1. *Enteral Nutrition; 2. *Parenteral Nutrition; 3. Infant Nutritional Physiological Phenomena; 4. Infant, Premature [*growth & development]; 5. Lactase [*therapeutic use]; 6. Lactose Intolerance [prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Weight Gain; | Provide MESH terms for the study
Lactase treated feeds to promote growth and feeding tolerance in preterm infants | You are a research assistant. Based on the question please provide appropriate answers |
1. Administration, Oral; 2. Eczema [*drug therapy]; 3. Histamine H1 Antagonists [*administration & dosage]; | Provide MESH terms for the study
Oral H1 antihistamines as monotherapy for eczema | You are a research assistant. Based on the question please provide appropriate answers |
1. Amlodipine [adverse effects]; 2. *beta-Thalassemia [complications, drug therapy]; 3. Calcium Channel Blockers [adverse effects]; 4. *Cardiomyopathies [etiology, prevention & control]; 5. Edema; 6. Ferritins; 7. Iron [therapeutic use]; 8. Iron Chelating Agents [adverse effects]; 9. *Iron Overload [complications, drug therapy, prevention & control]; | Provide MESH terms for the study
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta thalassaemia | You are a research assistant. Based on the question please provide appropriate answers |
1. Controlled Before-After Studies; 2. *Culicidae; 3. *Insecticides; 4. *Malaria, Falciparum; 5. Mosquito Vectors; | Provide MESH terms for the study
Topical repellents for malaria prevention | You are a research assistant. Based on the question please provide appropriate answers |
1. *Acute Chest Syndrome [chemically induced, complications, drug therapy]; 2. *Anemia, Sickle Cell [complications]; 3. Angiotensin-Converting Enzyme Inhibitors [therapeutic use]; 4. Antisickling Agents [therapeutic use]; 5. Ascorbic Acid [therapeutic use]; 6. Captopril [therapeutic use]; 7. Creatinine; 8. Hydroxyurea [therapeutic use]; 9. *Kidney Failure, Chronic; 10. Lisinopril [therapeutic use]; 11. Proteinuria [etiology]; | Provide MESH terms for the study
Interventions for chronic kidney disease in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. *Angiofibroma; 2. *Angiomyolipoma; 3. *Astrocytoma [drug therapy]; 4. Everolimus [adverse effects]; 5. *Kidney Neoplasms [drug therapy]; 6. MTOR Inhibitors; 7. Sirolimus [adverse effects]; 8. *Tuberous Sclerosis [complications, drug therapy]; | Provide MESH terms for the study
Rapamycin and rapalogs for tuberous sclerosis complex | You are a research assistant. Based on the question please provide appropriate answers |
1. Antilymphocyte Serum [therapeutic use]; 2. Bone Marrow Transplantation; 3. *Bronchiolitis Obliterans Syndrome; 4. *Graft vs Host Disease [prevention & control]; 5. *Hematopoietic Stem Cell Transplantation [adverse effects]; | Provide MESH terms for the study
Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults | You are a research assistant. Based on the question please provide appropriate answers |
1. Alendronate; 2. *beta-Thalassemia [complications, drug therapy]; 3. Clodronic Acid; 4. Denosumab [therapeutic use]; 5. Diphosphonates [therapeutic use]; 6. *Fractures, Bone; 7. *Osteoporosis [drug therapy, etiology]; 8. Pamidronate; | Provide MESH terms for the study
Treatment for osteoporosis in people with beta‐thalassaemia | You are a research assistant. Based on the question please provide appropriate answers |
1. *Gingivitis; 2. *Thalassemia [complications, therapy]; | Provide MESH terms for the study
Treatment of dental and orthodontic complications in thalassaemia | You are a research assistant. Based on the question please provide appropriate answers |
1. *beta-Thalassemia [therapy]; 2. Blood Transfusion; 3. Fetal Hemoglobin; 4. Hydroxyurea; 5. Resveratrol; | Provide MESH terms for the study
Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias | You are a research assistant. Based on the question please provide appropriate answers |
1. *Anemia, Sickle Cell [complications]; 2. *Choroidal Neovascularization [etiology]; 3. Intravitreal Injections; 4. *Laser Therapy [adverse effects]; 5. Quality of Life; 6. Vision Disorders; | Provide MESH terms for the study
Laser therapy for retinopathy in sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. *Acute Chest Syndrome [drug therapy, etiology]; 2. *Anemia, Sickle Cell [complications, drug therapy]; 3. *Asthma; 4. Bronchi; 5. Bronchodilator Agents [therapeutic use]; | Provide MESH terms for the study
Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Adrenal Cortex Hormones; 2. *Graft vs Host Disease [therapy]; 3. *Hematopoietic Stem Cell Transplantation [adverse effects]; 4. Methoxsalen [therapeutic use]; 5. *Photopheresis [methods]; 6. Steroids; | Provide MESH terms for the study
Extracorporeal photopheresis versus standard treatment for acute graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents | You are a research assistant. Based on the question please provide appropriate answers |
1. *Acute Chest Syndrome [chemically induced, complications, drug therapy]; 2. *Anemia, Sickle Cell [complications, drug therapy]; 3. Antisickling Agents [adverse effects]; 4. Hemoglobin, Sickle [therapeutic use]; 5. Hydroxyurea [adverse effects]; 6. Pain [drug therapy]; 7. *Stroke [prevention & control]; | Provide MESH terms for the study
Hydroxyurea (hydroxycarbamide) for sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Analgesics [therapeutic use]; 2. *Anemia, Sickle Cell; 3. *Nitric Oxide [therapeutic use]; 4. Oxygen; 5. Pain [drug therapy, etiology]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Inhaled nitric oxide for treating pain crises in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. *Antimalarials [adverse effects]; 2. *Artemisinins [adverse effects]; 3. Artesunate [therapeutic use]; 4. Bilirubin; 5. Drug Combinations; 6. *Malaria, Falciparum [drug therapy]; 7. Naphthyridines; | Provide MESH terms for the study
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria | You are a research assistant. Based on the question please provide appropriate answers |
1. *Anemia [drug therapy, etiology]; 2. Erythropoiesis; 3. *Hematinics [therapeutic use]; 4. *Hypertension; 5. Iron [therapeutic use]; 6. *Neoplasms [complications]; 7. Network Meta-Analysis; 8. *Thrombocytopenia; | Provide MESH terms for the study
Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis | You are a research assistant. Based on the question please provide appropriate answers |
1. Chronic Disease; 2. *Graft vs Host Disease [therapy]; 3. *Hematopoietic Stem Cell Transplantation [adverse effects]; 4. Methoxsalen; 5. *Photopheresis [adverse effects]; 6. Steroids; | Provide MESH terms for the study
Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents | You are a research assistant. Based on the question please provide appropriate answers |
1. *Insecticide-Treated Bednets; 2. *Insecticides; 3. *Malaria [prevention & control]; 4. Mosquito Control; 5. Mosquito Vectors; 6. Tanzania; | Provide MESH terms for the study
Indoor residual spraying for preventing malaria in communities using insecticide‐treated nets | You are a research assistant. Based on the question please provide appropriate answers |
1. *Albuminuria [drug therapy, etiology]; 2. *Anemia, Sickle Cell [complications, drug therapy]; 3. *Angiotensin-Converting Enzyme Inhibitors [therapeutic use]; 4. Angiotensins; 5. *Proteinuria [drug therapy, etiology]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. *Blood Coagulation Disorders; 2. Cesarean Section; 3. Fetus; 4. *Labor, Obstetric; 5. *Pregnancy Complications, Hematologic; | Provide MESH terms for the study
Maternal and foetal outcomes following natural vaginal versus caesarean section (c‐section) delivery in women with bleeding disorders and carriers | You are a research assistant. Based on the question please provide appropriate answers |
1. *Anemia, Sickle Cell [genetics]; 2. *Cystic Fibrosis [genetics]; 3. Risk Assessment; 4. *Tay-Sachs Disease [genetics]; 5. *Thalassemia; | Provide MESH terms for the study
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay‐Sachs disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Body Height; 2. Cross-Over Studies; 3. *Familial Hypophosphatemic Rickets [drug therapy]; 4. Growth Hormone; 5. *Human Growth Hormone [therapeutic use]; | Provide MESH terms for the study
Recombinant growth hormone therapy for X‐linked hypophosphatemia in children | You are a research assistant. Based on the question please provide appropriate answers |
1. *Antimalarials [adverse effects]; 2. *Malaria [drug therapy, epidemiology]; 3. *Malaria, Falciparum; 4. Mass Drug Administration; 5. Parasitemia [drug therapy]; | Provide MESH terms for the study
Mass drug administration for malaria | You are a research assistant. Based on the question please provide appropriate answers |
1. Enzyme Replacement Therapy; 2. *Mucopolysaccharidosis VI [drug therapy]; 3. *N-Acetylgalactosamine-4-Sulfatase; 4. Quality of Life; 5. Recombinant Proteins; | Provide MESH terms for the study
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI | You are a research assistant. Based on the question please provide appropriate answers |
1. Cell- and Tissue-Based Therapy; 2. Immunotherapy, Adoptive; 3. *Lymphoma, Large B-Cell, Diffuse [therapy]; 4. Neoplasm Recurrence, Local; 5. Observational Studies as Topic; 6. *Receptors, Chimeric Antigen; | Provide MESH terms for the study
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma | You are a research assistant. Based on the question please provide appropriate answers |
1. *Hemophilia A [drug therapy]; 2. Hemorrhage; 3. *Hemostatics; 4. Rituximab [therapeutic use]; | Provide MESH terms for the study
Rituximab for eradicating inhibitors in people with acquired haemophilia A | You are a research assistant. Based on the question please provide appropriate answers |
1. Blood Coagulation Factors [*therapeutic use]; 2. Factor VIII [*therapeutic use]; 3. Hemarthrosis [*prevention & control]; 4. Hemophilia A [*complications]; 5. Hemophilia B [*complications]; 6. *Pharmaceutical Preparations; | Provide MESH terms for the study
Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B | You are a research assistant. Based on the question please provide appropriate answers |
1. Africa South of the Sahara; 2. Amodiaquine [therapeutic use]; 3. Antimalarials [*therapeutic use]; 4. Artemisinins [therapeutic use]; 5. Bias; 6. Confidence Intervals; 7. Disease Eradication; 8. Drug Combinations; 9. Endemic Diseases [*prevention & control]; 10. Hospitalization [statistics & numerical data]; 11. Malaria [*prevention & control]; 12. Parasitemia [drug therapy]; 13. Pyrimethamine [therapeutic use]; 14. Quinolines [therapeutic use]; 15. Randomized Controlled Trials as Topic; 16. Sulfadoxine [therapeutic use]; | Provide MESH terms for the study
Intermittent preventive treatment for malaria in infants | You are a research assistant. Based on the question please provide appropriate answers |
1. beta-Thalassemia [*therapy]; 2. *Hematopoietic Stem Cell Transplantation; | Provide MESH terms for the study
Hematopoietic stem cell transplantation for people with β‐thalassaemia | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Hemolytic, Autoimmune [*drug therapy]; 2. Bias; 3. Confidence Intervals; 4. Drug Therapy, Combination [methods]; 5. Erythrocyte Transfusion; 6. Glucocorticoids [administration & dosage, *therapeutic use]; 7. Immunologic Factors [administration & dosage, *therapeutic use]; 8. Prednisolone [administration & dosage, *therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Rituximab [*therapeutic use]; | Provide MESH terms for the study
Disease‐modifying treatments for primary autoimmune haemolytic anaemia | You are a research assistant. Based on the question please provide appropriate answers |
1. Age Factors; 2. Anemia, Sickle Cell [*complications, genetics]; 3. *Antibiotic Prophylaxis [adverse effects]; 4. beta-Thalassemia [complications]; 5. Bias; 6. Hemoglobin SC Disease [complications]; 7. Homozygote; 8. Incidence; 9. Medication Adherence; 10. Penicillins [adverse effects, *therapeutic use]; 11. Pneumococcal Infections [epidemiology, mortality, *prevention & control]; 12. Randomized Controlled Trials as Topic; 13. Streptococcus pneumoniae; | Provide MESH terms for the study
Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Amodiaquine [therapeutic use]; 2. Antimalarials [*therapeutic use]; 3. Artemether, Lumefantrine Drug Combination [therapeutic use]; 4. Artemisinins [therapeutic use]; 5. Atovaquone [*therapeutic use]; 6. Cameroon; 7. Colombia; 8. Drug Combinations; 9. Ethiopia; 10. Malaria, Falciparum [*drug therapy]; 11. Mefloquine [therapeutic use]; 12. Proguanil [*therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Thailand; 15. Treatment Failure; | Provide MESH terms for the study
Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria | You are a research assistant. Based on the question please provide appropriate answers |
1. *Anemia, Sickle Cell [complications, therapy]; 2. Bandages; 3. *Leg Ulcer [etiology, therapy]; 4. Quality of Life; 5. Wound Healing; | Provide MESH terms for the study
Interventions for treating leg ulcers in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. *Dietary Supplements; 2. Intelligence [drug effects]; 3. Neuropsychological Tests; 4. Phenylalanine [blood]; 5. Phenylketonurias [blood, diet therapy, *drug therapy]; 6. Placebos [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Tyrosine [blood, *therapeutic use]; | Provide MESH terms for the study
Tyrosine supplementation for phenylketonuria | You are a research assistant. Based on the question please provide appropriate answers |
1. Antimalarials [adverse effects, *therapeutic use]; 2. Artemether, Lumefantrine Drug Combination [adverse effects, *therapeutic use]; 3. Artemisinins [adverse effects, *therapeutic use]; 4. Bias; 5. Confidence Intervals; 6. Drug Combinations; 7. Malaria, Falciparum [*drug therapy]; 8. Quinolines [adverse effects, *therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Suspensions; 11. Tablets; 12. Treatment Failure; 13. Vomiting [chemically induced, epidemiology]; | Provide MESH terms for the study
Paediatric formulations of artemisinin‐based combination therapies for treating uncomplicated malaria in children | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [genetics, *therapy]; 2. *Genetic Therapy; | Provide MESH terms for the study
Gene therapy for sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Amaranthaceae [chemistry]; 2. Anemia [chemically induced]; 3. Anemia, Sickle Cell [blood, *drug therapy]; 4. Antisickling Agents [adverse effects, *therapeutic use]; 5. Cajanus; 6. Clinical Trials, Phase II as Topic; 7. *Phytotherapy [adverse effects]; 8. Plant Extracts [adverse effects, *therapeutic use]; 9. Plant Roots [chemistry]; 10. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Phytomedicines (medicines derived from plants) for sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Antibodies; 2. Factor IX [antagonists & inhibitors, *immunology]; 3. Factor VIII [antagonists & inhibitors, *immunology]; 4. Hemophilia A [blood, *drug therapy]; 5. Hemophilia B [blood, *drug therapy]; 6. Immunologic Factors [*therapeutic use]; 7. Rituximab [*therapeutic use]; | Provide MESH terms for the study
Rituximab for treating inhibitors in people with inherited severe hemophilia | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [blood, *complications]; 2. Antisickling Agents [adverse effects, therapeutic use]; 3. Blood Transfusion; 4. Early Termination of Clinical Trials; 5. *Erythrocyte Transfusion [adverse effects]; 6. Hemoglobin, Sickle; 7. Hydroxyurea [adverse effects, therapeutic use]; 8. Iron Chelating Agents [therapeutic use]; 9. Phlebotomy [adverse effects]; 10. *Primary Prevention; 11. *Secondary Prevention; 12. Stroke [etiology, *prevention & control]; | Provide MESH terms for the study
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Intelligence; 2. Phenylalanine [*administration & dosage, blood]; 3. Phenylketonurias [blood, *diet therapy]; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome; 6. Withholding Treatment; | Provide MESH terms for the study
Dietary interventions for phenylketonuria | You are a research assistant. Based on the question please provide appropriate answers |
1. Acitretin [adverse effects, therapeutic use]; 2. Antineoplastic Agents [administration & dosage, adverse effects]; 3. Bexarotene [therapeutic use]; 4. Combined Modality Therapy [methods]; 5. Immunologic Factors [therapeutic use]; 6. Interferon-alpha [therapeutic use]; 7. Mycosis Fungoides [pathology, *therapy]; 8. Neoplasm Staging [methods]; 9. Photochemotherapy [methods]; 10. Photopheresis [methods]; 11. PUVA Therapy [methods]; 12. Randomized Controlled Trials as Topic; 13. Skin Neoplasms [pathology, *therapy]; | Provide MESH terms for the study
Interventions for mycosis fungoides | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [*surgery]; 2. *Hematopoietic Stem Cell Transplantation; | Provide MESH terms for the study
Hematopoietic stem cell transplantation for people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Acute Chest Syndrome [etiology]; 2. Adenoidectomy; 3. Anemia, Sickle Cell [blood, complications, *surgery]; 4. Blood Transfusion [*methods]; 5. Cholecystectomy [adverse effects]; 6. *Hemoglobin, Sickle; 7. Preoperative Care [*methods]; 8. Randomized Controlled Trials as Topic; 9. Tonsillectomy; 10. Transfusion Reaction; | Provide MESH terms for the study
Preoperative blood transfusions for sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [*complications]; 2. Cholestasis, Intrahepatic [etiology, *therapy]; | Provide MESH terms for the study
Interventions for treating intrahepatic cholestasis in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. beta-Thalassemia [*complications, genetics]; 2. Confidence Intervals; 3. Growth [*drug effects, physiology]; 4. Growth Disorders [*drug therapy, etiology]; 5. Homozygote; 6. Human Growth Hormone [*therapeutic use]; | Provide MESH terms for the study
Growth hormone therapy for people with thalassaemia | You are a research assistant. Based on the question please provide appropriate answers |
1. Administration, Oral; 2. Anemia, Sickle Cell [*blood, *complications]; 3. Bias; 4. Cholecalciferol [*administration & dosage, adverse effects]; 5. Pain [drug therapy]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Time Factors; 9. Vitamin D [*administration & dosage, adverse effects, *analogs & derivatives, blood]; 10. Vitamin D Deficiency [therapy]; | Provide MESH terms for the study
Vitamin D supplementation for sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. *Genetic Therapy; 2. Hemophilia A [*therapy]; 3. Hemophilia B [*therapy]; | Provide MESH terms for the study
Gene therapy for haemophilia | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [*complications, drug therapy]; 2. Antisickling Agents [adverse effects, *therapeutic use]; 3. Brain Infarction [etiology, *prevention & control]; 4. Cause of Death; 5. Cognition [physiology]; 6. *Erythrocyte Transfusion; 7. Hydroxyurea [adverse effects, *therapeutic use]; 8. *Phlebotomy [adverse effects]; 9. Primary Prevention [methods]; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Secondary Prevention [methods]; 13. Stroke [prevention & control]; | Provide MESH terms for the study
Interventions for preventing silent cerebral infarcts in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Analgesics [therapeutic use]; 2. Anemia, Sickle Cell [physiopathology]; 3. Chronic Pain [etiology, *therapy]; 4. Pain Management [*methods]; 5. Randomized Controlled Trials as Topic; 6. Transcutaneous Electric Nerve Stimulation [*methods]; | Provide MESH terms for the study
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Neonatal [blood, prevention & control]; 2. Enterocolitis, Necrotizing [blood, prevention & control]; 3. Erythropoiesis; 4. Erythropoietin [administration & dosage, blood]; 5. Hematinics [*administration & dosage]; 6. Infant, Low Birth Weight [*blood]; 7. Infant, Premature [*blood]; 8. Randomized Controlled Trials as Topic; 9. Retinopathy of Prematurity [blood, prevention & control]; | Provide MESH terms for the study
Early erythropoiesis‐stimulating agents in preterm or low birth weight infants | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Neonatal [blood, prevention & control]; 2. *Erythrocyte Transfusion; 3. Hematinics [administration & dosage, *therapeutic use]; 4. Infant, Low Birth Weight [*blood]; 5. Infant, Premature [*blood]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants | You are a research assistant. Based on the question please provide appropriate answers |
1. Acute Chest Syndrome [etiology, mortality, *therapy]; 2. Anemia, Sickle Cell [*complications]; 3. *Blood Transfusion; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome; | Provide MESH terms for the study
Blood transfusions for treating acute chest syndrome in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. *Iron Deficiencies; 2. Hemoglobins [*metabolism]; 3. Infusions, Intravenous; 4. Iron [*therapeutic use]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Intravenous iron therapy for non‐anaemic, iron‐deficient adults | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [*complications]; 2. Craniofacial Abnormalities [complications]; 3. Dental Care [*methods]; 4. Randomized Controlled Trials as Topic; 5. Tooth Diseases [*etiology, therapy]; | Provide MESH terms for the study
Treatment of dental complications in sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [*complications]; 2. Osteonecrosis [*etiology, *therapy]; 3. Physical Therapy Modalities; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Treatment for avascular necrosis of bone in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Blood Component Transfusion [*methods]; 3. Hemorrhage [*prevention & control]; 4. Hemostatics [therapeutic use]; 5. Plasma; 6. Preoperative Care; 7. Randomized Controlled Trials as Topic; 8. *Surgical Procedures, Operative; 9. Thrombelastography; | Provide MESH terms for the study
Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non‐cardiac surgery or invasive procedures | You are a research assistant. Based on the question please provide appropriate answers |
1. Antibodies, Monoclonal [therapeutic use]; 2. Antineoplastic Agents [*therapeutic use]; 3. Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; 4. Bortezomib [therapeutic use]; 5. Lenalidomide [therapeutic use]; 6. Multiple Myeloma [*drug therapy]; 7. Network Meta-Analysis; 8. Randomized Controlled Trials as Topic; 9. Thalidomide [therapeutic use]; | Provide MESH terms for the study
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis | You are a research assistant. Based on the question please provide appropriate answers |
1. Acute Pain [*drug therapy, *etiology]; 2. Analgesics [*therapeutic use]; 3. Analgesics, Opioid [therapeutic use]; 4. Anemia, Sickle Cell [*complications]; 5. Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; 6. Pain Management [methods]; 7. Pain Measurement; 8. Peripheral Vascular Diseases [drug therapy, etiology]; 9. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Pharmacological interventions for painful sickle cell vaso‐occlusive crises in adults | You are a research assistant. Based on the question please provide appropriate answers |
1. Cholesterol, LDL [blood]; 2. Hydroxymethylglutaryl-CoA Reductase Inhibitors [adverse effects, *therapeutic use]; 3. Hyperlipoproteinemia Type II [blood, *drug therapy, genetics]; 4. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Statins for children with familial hypercholesterolemia | You are a research assistant. Based on the question please provide appropriate answers |
1. Acute Chest Syndrome [etiology, *therapy]; 2. Anemia, Sickle Cell [*complications]; 3. Antisickling Agents [therapeutic use]; 4. Erythrocyte Transfusion [*methods]; 5. Hypertension, Pulmonary [etiology, *therapy]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [*complications]; 2. Anti-Bacterial Agents [*therapeutic use]; 3. Osteomyelitis [*drug therapy]; | Provide MESH terms for the study
Antibiotics for treating osteomyelitis in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. beta-Thalassemia [*surgery]; 2. Blood Transfusion; 3. *Laparoscopy; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Splenectomy [*methods]; | Provide MESH terms for the study
Splenectomy for people with thalassaemia major or intermedia | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [blood, *drug therapy]; 2. Antisickling Agents [*therapeutic use]; 3. Hydroxyurea [therapeutic use]; 4. Magnesium [blood, *therapeutic use]; 5. Magnesium Sulfate [therapeutic use]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Magnesium for treating sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Antifibrinolytic Agents [*therapeutic use]; 2. Hemophilia A [*complications, drug therapy]; 3. Minor Surgical Procedures [adverse effects]; 4. Oral Hemorrhage [*prevention & control]; 5. Postoperative Hemorrhage [prevention & control]; 6. Surgery, Oral; 7. Tooth Extraction [adverse effects]; 8. von Willebrand Diseases [*complications]; | Provide MESH terms for the study
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions | You are a research assistant. Based on the question please provide appropriate answers |
1. beta-Thalassemia [*drug therapy]; 2. Blood Transfusion [*statistics & numerical data]; 3. Hematinics [adverse effects, *therapeutic use]; 4. Hydroxyurea [adverse effects, *therapeutic use]; | Provide MESH terms for the study
Hydroxyurea (hydroxycarbamide) for transfusion‐dependent β‐thalassaemia | You are a research assistant. Based on the question please provide appropriate answers |
1. Blood Coagulation Disorders [congenital, *drug therapy, *prevention & control]; 2. Deamino Arginine Vasopressin [*therapeutic use]; 3. Hemostatics [*therapeutic use]; 4. Pregnancy Complications, Hematologic [*drug therapy, *prevention & control]; | Provide MESH terms for the study
Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders | You are a research assistant. Based on the question please provide appropriate answers |
1. *Exercise; 2. Exercise Tolerance; 3. Feasibility Studies; 4. Hematologic Neoplasms [complications, mortality, *rehabilitation]; 5. Physical Conditioning, Human; 6. Qigong; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Resistance Training; 10. Tai Ji; 11. Yoga; | Provide MESH terms for the study
Aerobic physical exercise for adult patients with haematological malignancies | You are a research assistant. Based on the question please provide appropriate answers |
1. Acute Disease; 2. beta-Thalassemia [*therapy]; 3. Chronic Disease; 4. Graft vs Host Disease [epidemiology, *therapy]; 5. Hematologic Neoplasms [mortality, *therapy]; 6. Hematopoietic Stem Cell Transplantation [*adverse effects]; 7. Incidence; 8. *Mesenchymal Stem Cell Transplantation [mortality]; 9. Randomized Controlled Trials as Topic; 10. Recurrence; | Provide MESH terms for the study
Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition | You are a research assistant. Based on the question please provide appropriate answers |
1. Anti-Bacterial Agents [*therapeutic use]; 2. Drug Resistance, Bacterial; 3. Febrile Neutropenia [*drug therapy, mortality]; 4. Neoplasms [*complications]; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome; 7. *Withholding Treatment; | Provide MESH terms for the study
Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Blood Coagulation Factors [*therapeutic use]; 2. Cause of Death; 3. Factor XIII [*therapeutic use]; 4. Fibrinogen [*therapeutic use]; 5. Hemorrhage [mortality, prevention & control, *therapy]; 6. Hemostatics [*therapeutic use]; 7. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [*complications]; 2. Salmonella Infections [*prevention & control]; 3. Salmonella Vaccines [*administration & dosage]; | Provide MESH terms for the study
Vaccines for preventing invasive salmonella infections in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Cause of Death; 2. Insecticide Resistance; 3. *Insecticide-Treated Bednets; 4. Malaria [mortality, *prevention & control]; 5. Malaria, Falciparum [mortality, prevention & control]; 6. Malaria, Vivax [mortality, prevention & control]; 7. Mosquito Control [*methods]; 8. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Insecticide‐treated nets for preventing malaria | You are a research assistant. Based on the question please provide appropriate answers |
1. Acetamides [*therapeutic use]; 2. Anemia, Sickle Cell [*blood, complications]; 3. Antisickling Agents [*therapeutic use]; 4. Clinical Trials, Phase II as Topic; 5. Clinical Trials, Phase III as Topic; 6. Dehydration [*prevention & control]; 7. Early Termination of Clinical Trials; 8. Erythrocyte Aging [drug effects]; 9. Erythrocytes [*drug effects]; 10. Piracetam [therapeutic use]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Trityl Compounds [*therapeutic use]; 14. Zinc Sulfate [*therapeutic use]; | Provide MESH terms for the study
Drugs for preventing red blood cell dehydration in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Benzoates [therapeutic use]; 2. Deamino Arginine Vasopressin [therapeutic use]; 3. Hemostatics [therapeutic use]; 4. Hydrazines [therapeutic use]; 5. Plasma; 6. Platelet Transfusion [*methods]; 7. Postoperative Care [methods]; 8. Postoperative Hemorrhage [*prevention & control]; 9. Pyrazoles [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Receptors, Fc [therapeutic use]; 12. Recombinant Fusion Proteins [therapeutic use]; 13. Thrombocytopenia [complications, *therapy]; 14. Thrombopoietin [therapeutic use]; | Provide MESH terms for the study
Prophylactic platelet transfusions prior to surgery for people with a low platelet count | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [*complications]; 2. Bacterial Capsules [immunology]; 3. Haemophilus Infections [*prevention & control]; 4. Haemophilus influenzae type b [*immunology]; 5. Haemophilus Vaccines [*administration & dosage, immunology]; 6. Vaccines, Conjugate [administration & dosage, immunology]; | Provide MESH terms for the study
Conjugate Haemophilus influenzae type b vaccines for sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [adverse effects, *therapeutic use]; 2. Decitabine [adverse effects, therapeutic use]; 3. Diarrhea [chemically induced]; 4. Disease Progression; 5. Heart [drug effects]; 6. Infections [chemically induced]; 7. Leukemia, Myeloid, Acute [*drug therapy, mortality]; 8. Nausea [chemically induced]; 9. Recurrence; 10. Tretinoin [adverse effects, *therapeutic use]; 11. Vomiting [chemically induced]; | Provide MESH terms for the study
Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (non‐APL)) | You are a research assistant. Based on the question please provide appropriate answers |
1. Myelodysplastic Syndromes [congenital, *therapy]; 2. Platelet Transfusion [*methods]; | Provide MESH terms for the study
Comparison of a therapeutic‐only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [blood, *drug therapy]; 2. Double-Blind Method; 3. Erythrocyte Indices; 4. Folic Acid [*administration & dosage, blood]; 5. Growth; 6. Hematinics [*administration & dosage]; | Provide MESH terms for the study
Folate supplementation in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. *Culicidae; 2. *Insect Repellents; 3. *Protective Clothing; 4. Incidence; 5. Insecticide‐Treated Bednets; 6. Malaria, Falciparum [epidemiology, *prevention & control]; 7. Malaria, Vivax [epidemiology, *prevention & control]; 8. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Mosquito repellents for malaria prevention | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [*therapeutic use]; 2. Bone Density Conservation Agents [*therapeutic use]; 3. Bone Diseases [*drug therapy, mortality]; 4. Clodronic Acid [therapeutic use]; 5. Diphosphonates [*therapeutic use]; 6. Disease‐Free Survival; 7. Etidronic Acid [therapeutic use]; 8. Fractures, Bone [epidemiology, prevention & control]; 9. Imidazoles [therapeutic use]; 10. Multiple Myeloma [complications, *drug therapy, mortality]; 11. Pamidronate; 12. Randomized Controlled Trials as Topic; 13. Spinal Fractures [epidemiology, prevention & control]; 14. Zoledronic Acid; | Provide MESH terms for the study
Bisphosphonates in multiple myeloma: an updated network meta‐analysis | You are a research assistant. Based on the question please provide appropriate answers |
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 4